# US 2026/0083761 A1 · Pharmaceutical composition for treating brain disease, neuronal migration promoter, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083761 A1
- Document ID: US20260083761A1
- Status: Published application
- Kind: A1
- Application number: 19/110,266
- Filed: 2023-09-08
- Published: 2026-03-26
- Earliest claimed: 2022-09-12
- Assignees: Public University Corporation Nagoya City University
- Applicants: Public University Corporation Nagoya City University
- Inventors: Kazunobu SAWAMOTO; Mami MATSUMOTO
- Web page: https://patentgrep.com/patent/US20260083761A1

## CPC

- A61K 31/7012: Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K31/191; ascorbic acid A61K31/375)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a technology capable of promoting migration of neurons. This pharmaceutical composition for treating a brain disease includes a neuraminidase inhibitor, this neuronal migration promoter includes a neuraminidase inhibitor, and this method of promoting migration of neurons includes a step of bringing a neuraminidase inhibitor into contact with neurons.

## Claims

### Claim 1

A pharmaceutical composition for treating a brain disease, comprising a neuraminidase inhibitor.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the neuraminidase inhibitor inhibits at least one of Neu1 or Neu4.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein administration starts before a lapse of 10 days from an onset of the brain disease and is performed daily.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition is administered for 10 days or longer.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered in a form of an injection.

### Claim 6

A neuronal migration promoter comprising a neuraminidase inhibitor.

### Claim 7 (depends on 6)

The neuronal migration promoter according to claim 6, wherein the neuraminidase inhibitor inhibits at least one of Neu1 or Neu4.

### Claim 8

A method of treating a brain disease, comprising a step of administering a neuraminidase inhibitor to a brain disease patient.

### Claim 9

A method of promoting migration of neurons, comprising a step of bringing a neuraminidase inhibitor into contact with the neurons.

### Claim 10

Use of a neuraminidase inhibitor for treatment of a brain disease.
